Stifel analyst Justin Keywood raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$20 from C$17 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPHRF:
- Cipher Pharmaceuticals price target raised to C$14 from C$13 at Canaccord
- Cipher Pharmaceuticals Reports Record Q2 2025 Revenue
- Cipher Pharmaceuticals Achieves Record Revenue in Q2 2025
- Cipher Pharmaceuticals to Announce Q2 2025 Financial Results
- Cipher Pharmaceuticals’ Shareholders Approve Key Resolutions at Annual Meeting